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Abstract
Background:  Standardization of cell-based immunologic monitoring is becoming increasingly
important as methods for measuring cellular immunity become more complex. We assessed the
ability of two commonly used cell-based assays, tritiated thymidine incorporation (proliferation)
and IFN-gamma ELISPOT, to predict T cell responses to HER-2/neu, tetanus toxoid (tt), and
cytomegalovirus (CMV) antigens. These antigens were determined to be low (HER-2/neu),
moderate (tt), and robustly (CMV) immunogenic proteins. Samples from 27 Stage II, III, and IV HER-
2/neu positive breast cancer patients, vaccinated against the HER-2/neu protein and tt, were
analyzed by tritiated thymidine incorporation and IFN-gamma ELISPOT for T cell response.
Results: Linear regression analysis indicates that both stimulation index (SI) (p = 0.011) and IFN-
gamma secreting precursor frequency (p < 0.001) are significant indicators of antigen specific
immunity. ROC curves plotted to assess the performance of tritiated thymidine incorporation and
the ELISPOT assay indicate that SI is a significant indicator of low T cell response to the HER-2/neu
vaccine (p = 0.05), and of moderate and robust responses to tt (p = 0.01) and CMV (p = 0.016),
respectively. IFN-gamma precursor frequency is a significant indicator of a robust T cell response
to CMV (p = 0.03), but not of moderate tt (p = 0.09), or low HER-2/neu (p = 0.09) T cell responses.
Conclusion: These data underscore the importance of taking into consideration the performance
characteristics of assays used to measure T cell immunity. This consideration is particularly
necessary when determining which method to utilize for assessing responses to
immunotherapeutic manipulations in cancer patients.
Background
A multitude of assays have been developed to measure T
cell responses to a variety of antigens [1]. There is little
agreement as to which method is the most superior for
detecting immune responses. Antigen specific T cell prolif-
eration as measured by tritiated thymidine incorporation
and IFN-gamma ELISPOT are two of the most commonly
used methods to measure T cell immunity. We questioned
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if there was a difference in the ability of these assays to
measure a broad range of T cell responses.
In this study we utilized T cells from cancer patients that
had been immunized with both a HER-2/neu protein
based vaccine as well as a tetanus toxoid vaccine. Both vac-
cines were successful in generating antigen specific anti-
body immunity, an indicator of immunization.
Evaluating three immunogenic proteins, HER-2/neu, tt,
and CMV in these patients as representative of low, inter-
mediate, and robust responses we determined that the
proliferation assay was a better discriminator of low level
immune responses than ELISPOT. These data highlight
the need for immunologic monitoring core laboratories
to define the performance characteristics of the methods
chosen to assess the development of a T cell immune
response.
Results
Antibody immunity to both foreign and tumor antigens is 
an indicator of a concomitant T cell response
A standard measure of successful immunization is the
development of antigen specific humoral immunity [2].
Furthermore, the presence of humoral immunity may
serve as a marker for the presence of antigen specific CD4+
T cells [3,4]. Breast cancer patients were immunized
against the HER-2/neu ICD protein and tt, and humoral
immunity to these antigens measured by ELISA. Antibody
responses to CMV, a viral antigen presumed to stimulate
a robust immune reaction, were also measured by ELISA
[5]. Successful immunization against HER-2/neu, as indi-
cated by the presence of HER-2/neu specific antibodies,
was achieved in 89% (24 of 27) of patients. Successful
immunization against tt, as indicated by the presence of tt
specific antibodies, was achieved in 100% of patients.
Forty-four percent of the patients were CMV seropositive.
Linear regression analysis of all results was performed to
determine the correlation of antibody immunity to a
detectable T cell response. Antibody response predicted T
cell response when T cell response was assessed by either
proliferation assay (Fig. 1A) or ELISPOT assay (Fig. 1B).
Humoral immunity significantly (p = 0.011) predicted
CD4+ T cell proliferation with an R2  of 0.428, and
humoral immunity significantly (p < 0.001) predicted
IFN-gamma secretion with an R2 of 0.531. Thus, humoral
immunity and T cell immunity correlated in both foreign
and tumor antigen systems.
The magnitude of the T cell response differed significantly
between antigens (Fig. 2). The range of T cell immunity to
HER-2/neu was low to moderate with a mean SI of 5.06
(1.6–15.8) and a mean precursor frequency of 4.61 pre-
cursors/106 PBMC (0–46). Responses to tt were moderate
to robust with a mean SI of 23.4 (0.9–76.2) and mean
precursor frequency of 146 precursors/106  PBMC (0–
1153). Responses to CMV were robust with a mean SI of
47.1 (0.7–296) and a mean precursor frequency of 329
precursors/106  PBMC (0–1037). Mean antibody
responses to HER-2/neu, tt and CMV were 3.3 (0–9.3) ug/
ml, 47 (8.9–70.7) ug/ml and 131 (0–1000) ug/ml, respec-
tively. We questioned the sensitivity of these two assays,
CD4+ proliferation and IFN-gamma ELISPOT, in detect-
ing this wide range of responses.
T cell proliferation will detect T cell immunity whether the 
immune response is low, moderate or robust
ROC curves were plotted to assess sensitivity and specifi-
city of the proliferation assay, using presence of antigen
specific antibodies as a marker of successful immuniza-
tion. Results show that SI is a significant (p = 0.05) predic-
Antibody immunity to both foreign and tumor antigens is an  indicator of a concomitant T cell response Figure 1
Antibody immunity to both foreign and tumor anti-
gens is an indicator of a concomitant T cell response. 
Results from the (A) proliferation assay and (B) ELISPOT 
assay for antigens HER-2/neu, tt and CMV are plotted on the 
log-scaled horizontal axis. Antigen specific IgG antibody 
responses are plotted on the log-scaled vertical axis. The 
diagonal line indicates line of regression.
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tor of immunity to the HER-2/neu ICD protein with an
AUC of 0.773 (Fig. 3A). This yielded a sensitivity of 83%.
A subset (n = 18) of these patients was assessed by prolif-
eration assay for cellular immunity to antigens tt and
CMV. Results show that SI is a significant indicator of
moderate cellular immunity to tt (AUC = 0.883, p =
0.010) (Fig. 3B) with a sensitivity of 100%, and CMV
(AUC = 0.844, p = 0.016) with a sensitivity of 100% (Fig.
3C). Only 1 CMV seronegative patient had a positive CMV
specific SI. Thus, the proliferation assay is capable of accu-
rately detecting low, moderate, and robust T cell immu-
nity.
IFN-gamma secretion as measured by ELISPOT accurately 
detects robust T cell immunity
ROC curves were plotted to assess sensitivity and specifi-
city of the ELISPOT assay, using presence of antigen spe-
cific antibodies as a marker of successful immunization.
Results show that ELISPOT did not significantly detect
low level immunity to HER-2/neu or tt. Precursor fre-
quency is not a significant (p = 0.09) indicator of immu-
nity to the HER-2/neu ICD protein with an AUC of 0.800
(Fig. 4A) and sensitivity of 64%. A subset (n = 12) of these
patients was assessed by ELISPOT assay for cellular immu-
nity to antigens tt and CMV. Results show that precursor
frequency is not a significant indicator of moderate level
cellular immunity to tt (AUC = 0.900, p = 0.09) (Fig. 4B),
but that ELISPOT will significantly (p = 0.016) predict
robust T cell immunity to CMV with an AUC of 0.844 (Fig.
T cell proliferation will detect T cell immunity whether the  immune response is low, moderate or robust Figure 3
T cell proliferation will detect T cell immunity 
whether the immune response is low, moderate or 
robust. ROC curves were plotted to assess the diagnostic 
performance of the proliferation assay for (A) HER-2/neu 
ICD specific cellular immunity (n = 27), (B) tt specific cellular 
immunity (n = 18), and (C) CMV specific cellular immunity (n 
= 18). Samples with antigen specific circulating antibodies 
were considered to have positive immunity.
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Magnitude of T cell response differs significantly between  antigens Figure 2
Magnitude of T cell response differs significantly 
between antigens. Boxes represent responses to the pro-
liferation assay and ELISPOT assay for antigens HER-2/neu 
(closed boxes), tt (open boxes), and CMV (shaded boxes). 
Reporting value for the proliferation assay is SI, and reporting 
value for the ELISPOT assay is antigen-specific precursor/106 
PBMC. Antibody immunity for the same group of subjects is 
shown for comparison, with a reporting value of ug/ml anti-
gen specific IgG.
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4C). The sensitivity for the ELISPOT tt and CMV assays
were 67% and 88%, respectively. Thus, the ELISPOT assay
is most accurate when assessing robust T cell immunity.
There were few false positives in this population. That is,
patients without an antibody response usually lacked a T
cell response as well, by either T cell assay method. A cut-
off of 2.0 for SI for the proliferation assay for HER-2/neu
specific CD4+ T cells accurately identified 78% of serop-
ositive and seronegative samples, with 2 false positives
and 4 false negatives. The HER-2/neu ELISPOT accurately
identified 56% of seropositive and seronegative samples,
with 3 false positives and 5 false negatives. The tt prolifer-
ation assay correctly identified all samples, and the tt
ELISPOT 67%, with 4 false negatives. The CMV prolifera-
tion assay correctly identified 88% with 2 false positive
samples, and the CMV ELISPOT correctly identified 92%
of samples, with 1 false negative.
Discussion
While infectious disease antigens, in general, stimulate a
very robust T cell immune response that can easily be
detected using a variety of assays, immunity to tumor anti-
gens is generally low level. For this reason, to evaluate the
immune response against cancer antigens, assays are
needed that can detect a broad range of T cell responses
i.e. from innate to induced immunity. We focused on
evaluating the sensitivity of two commonly used methods
for assessing tumor specific immunity; the proliferation of
T cells after antigen exposure measured by the incorpora-
tion of tritiated thymidine and IFN-gamma ELISPOT.
Compared to other methods of T cell assessment, such as
flow cytometry or tetramer analysis, these assays are tech-
nically simple, easy to perform for all levels of lab person-
nel, require smaller numbers of cells, and reagents which
are readily available and inexpensive.
Very few studies have attempted to determine the sensitiv-
ity and specificity of assays that measure cellular immune
responses after vaccination. A major problem preventing
such an analysis is the definition of a parameter that pre-
dicts that immunity has been successfully elicited. We
used the development of humoral immunity to indicate
that tumor antigen and foreign antigen vaccinations were
effective in stimulating a detectable immune response.
Humoral immunity has long been used as an accepted
measure of successful immunization. Presence of antigen
specific antibodies indicates exposure to antigen and as
such is considered proof of immunity (via natural expo-
sure or vaccination) to common infectious diseases such
as measles and influenza [6,7]. Vaccine development for
infectious disease continues to rely on antibody presence
as an indicator not only of exposure to antigen [8], but as
a surrogate of protection against disease. Indeed, antigen
specific humoral immunity is an indicator for the devel-
IFN-gamma secretion as measured by ELISPOT accurately  detects robust T cell immunity Figure 4
IFN-gamma secretion as measured by ELISPOT 
accurately detects robust T cell immunity. ROC 
curves were plotted to assess the diagnostic performance of 
the ELISPOT assay for (A) HER-2/neu ICD specific cellular 
immunity (n = 18), (B) tt specific cellular immunity (n = 12), 
and (C) CMV specific cellular immunity (n = 12). Samples 
with antigen specific circulating antibodies were considered 
to have positive immunity.
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opment of an antigen specific T cell response. In one
study, T cell responses measured by IFN-gamma ELISPOT
were significantly associated with antibody responses
induced by vaccination against P. falciparum protein [9]. A
recent population-based analysis of immune responses to
MMR vaccination found that an antigen specific antibody
response was significantly associated with antigen specific
T cell proliferation, and that lymphoproliferation was in
turn associated with production of IFN-gamma as meas-
ured by cytokine ELISA [7]. Thus, although not a perfect
measure or "gold standard", humoral immunity can be
used as a meaningful determinate of effective immuniza-
tion by which the T cell assays could be assessed and com-
pared.
Antibody responses to tumor associated antigen demon-
strate exposure to tumor, and may be significantly associ-
ated with antigen specific cellular responses. However, the
relationship between presence of antigen specific antibod-
ies, presence of antigen specific T cells, and clinical
response in cancer is not as well characterized as the rela-
tionship between antibody and T cell responses, and clin-
ical response in infectious diseases such as malaria.
Recently, the presence of tumor-infiltrating T cells has
recently been associated with clinical response in various
cancers, and antigen specific T cells have been shown nec-
essary for tumor destruction [10-12]. Thus, direct assay of
T cell responses, both in terms of measuring quantities
and frequencies of T cells and in terms of characterizing T
cell function, remains an essential component in elucidat-
ing the relationship between immune responses and clin-
ical outcome, and in the immunologic monitoring of
clinical trials.
Due to the large number of cells required to perform the
proliferation and ELISPOT assays, not all of the samples
contained sufficient quantity to perform both assays. It is
interesting to note that although the ELISPOT assay for
response to CMV tested only 12 samples, compared to the
18 samples tested for CMV responses by proliferation
assay, both methods produced results which predicted
positive humoral immunity to CMV. In contrast, all 27
samples were tested for HER-2/neu specific responses
using both ELISPOT and proliferation assays, and only the
proliferation assay produced results which were a signifi-
cant predictor of antibody immunity. It is possible that
the lack of concordance between tt specific results by ELIS-
POT and tt specific antibody immunity is due to the dif-
ference in samples size between T cell assays, as only 12
samples were of sufficient quantity to obtain results by
ELISPOT, compared to the 18 available for testing by pro-
liferation assay. Similarly, cell quantities limited the ELIS-
POT assay to measurement of only IFN-gamma. This may
in part explain the ELISPOT's lack of sensitivity in deter-
mining low level responses. Although increasing the
breadth of cytokine analysis to include measurement of
other cytokine responses such as IL-4 or IL-5 may lead to
greater sensitivity, the measurement of IFN-gamma alone
is standard for most clinical trials.
Conclusion
The antigens we chose to evaluate, HER-2/neu, tt, and
CMV, represented a broad range of responses, from low
level to robust. As the majority of patients developed
humoral immunity to both HER-2/neu and tt we were
able to evaluate the two cell based analytic methods for
the ability to detect low level T cell immunity. Antigen
specific T cell proliferation discriminated a broader range
of responses than ELISPOT. There have been few studies
directly comparing T cell assays. One recent study, Karls-
son et al in 2003, compared ELISPOT to cytokine flow
cytometry and found a lack of association between results
when considering low level responses, and that the ELIS-
POT assay performed better in detecting such responses
[13]. Other groups compared thymidine incorporation
proliferation assays to BrdU ELISA [14] or CFSE prolifera-
tion assay [15]. The first study found the BrdU ELISA per-
formance superior to traditional proliferation assay in
detecting low level responses; however, the study involved
only cells obtained from rat lymph nodes, not human
PBMC. The second study specifically looked at rare anti-
gen specific T cells in human PBMC and found the CFSE
assay had superior sensitivity within a small sample set.
The only study available which evaluates ELISPOT and
proliferation assays found that the proliferation assay was
not sensitive enough to detect CA-125 specific T cells in 4
healthy controls or 3 patients with ovarian cancer [16].
Data presented here, on a much larger number of individ-
uals who have documented evidence of successful immu-
nization, would suggest that there are marked differences
in the ability of two of the most common cellular immu-
nologic monitoring methods in measuring different levels
of T cell immunity. These considerations should be taken
into account when choosing analytic methods for assess-
ing the development of T cell immunity, particularly
when evaluating tumor specific immune responses which
are, for the most part, of low to moderate magnitude.
Methods
Subjects
Twenty-seven women with Stage II, III, or IV HER-2/neu
overexpressing breast cancer with no evidence of disease
after standard therapy, or stage IIC HER-2/neu overex-
pressing ovarian cancer in complete remission, were
enrolled on a phase I study of a HER-2/neu intracellular
domain (ICD) protein based vaccine [5]. Median subject
age was 49 years (35–76). The study was approved by
both the United States Food and Drug Administration and
the University of Washington Institutional Review Board.
Patients received intradermal (id.) vaccinations with theBMC Immunology 2007, 8:21 http://www.biomedcentral.com/1471-2172/8/21
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ICD protein monthly for 6 months. All patients received a
tetanus toxoid (tt) booster vaccination prior to beginning
immunization with the HER-2/neu protein vaccine.
Blood was obtained for assessment of immunologic
responses after the last vaccination. After processing,
PBMC samples were frozen and stored until time of assay.
Samples from all 27 patients were available for analysis of
HER-2/neu specific T cell response by a proliferation assay
that has been previously described [14]. As immunologic
assays were prioritized based on number of available cells,
samples from 18 of the 27 were available for analysis of tt
and CMV specific responses by proliferation assay and for
analysis of HER-2/neu specific response by ELISPOT.
Samples from 12 of the 27 were available for analysis of
tetanus toxoid and CMV specific response by ELISPOT. All
27 of the samples were run through the proliferation assay
for HER-2/neu T cell responses.
Modified limiting dilution tritiated thymidine 
incorporation (proliferation) assay
The CD4+ proliferation assay was modified from a previ-
ously described [17] assay for CD8+ T cells. The assay is
performed in 24-well replicates. PBMC were isolated from
heparinized peripheral blood by Ficoll/Hypaque-density
gradient centrifugation. Briefly, 2 × 105 PBMCs/well were
plated into 96-well plates in 24-well replicates in media
consisting of equal parts EHAA 120 (Biofluids, Rockville,
MD) and RPMI 1640 (Life Technologies, Inc., Gaithers-
burg, MD) with L-glutamine, penicillin/streptomycin, 2
ME, and 10% AB serum (ICN Flow, Costa Mesa, CA) in
the presence or absence of 25 ug/ml HER-2/neu ICD pro-
tein (Corixa Corp., Seattle, WA), 0.5 U/ml tetanus toxoid
(Lederle, Pearl river, NY), or 2.5 ug/ml CMV lysate (East-
Coast Bio, North Berwick, ME). After 5 days, wells were
pulsed with 1 uCi of [3H]thymidine for 8–10 h and
counted. Stimulation index (SI) is defined as the mean
CPM of the response of the antigen-stimulated cells
divided by the mean of the response of cells cultured with-
out antigen. Positive and negative controls were run on
each plate. Phytohemagglutinin (Sigma, St. Louis, MO)
incubated with patient T cells was used as a positive con-
trol to assess the ability of the T cells to respond to
mitogen. Media alone was used as a negative control in
addition to no antigens wells, and myoglobin (Chemi-
con, Temecula, CA) was used as an irrelevant protein. A
reference population of 30 age-matched volunteer donors
was previously used to establish base line response to all
antigens [5]. The mean and 3 SDs for the normal popula-
tion resulted in an SI of 1.98, therefore an SI greater than
2.0 was considered consistent with an immunized
response.
IFN-gamma enzyme-linked immunosorbent spot 
(ELISPOT) assay
An IFN-gamma ELISPOT assay was used to determine pre-
cursor frequencies of antigen-specific T lymphocytes as
previously described [18]. Briefly, on day 1, 2.5 × 105
PBMCs/well were plated into 96-well plates in six-well
replicates in 200 ul of RPMI-1640 containing L-
glutamine, penicillin, streptomycin, and 10% AB serum
(T-cell medium) in the presence or absence of 10 µg/ml
peptide antigen (Corixa), CMV lysate (EastCoast Bio) or
0.5 U/ml tetanus toxoid (Lederle). The cells were incu-
bated at 37°C at 5% CO2. On day 5, IL-2 was added to 10
U/ml. On day 8, 2.5 × 105/well irradiated autologous
PBMCs and 10 ug/ml antigens were added. Also on day 8,
nitrocellulose-backed 96-well plates (NC-plates) were
coated with 10 ug/ml anti-IFN-gamma Ab in PBS at 50 ul/
well. On day 9 the NC-plate was washed three times with
PBS and blocked for 2 hours with PBS containing 2% BSA,
followed by three washes with PBS. On day 9, the cells
were gently resuspended, pooled, centrifuged, and the
media was replaced. The cells were transferred into the
NC-plate in a volume of 100 ul/well in T-cell medium.
The NC-plate was incubated at 37°C for a further 20–24
hours followed by washing three times using PBS contain-
ing 0.05% Tween-20. The plate was then incubated for 2.5
hours at room temperature in 50 ul/well PBS containing 5
ug/ml biotinylated anti-IFN-gamma Ab, washed three
times with PBS, and further incubated with 100 ul/well
streptavidin-alkaline phosphatase at a dilution of 1:1,000
in PBS for 2 hours at room temperature. After washing
three times in PBS, the plate was incubated with 100 ul/
well AP-colorimetric substrate for 20–30 minutes, rinsed
with cool tap water, and allowed to dry completely. After
assay completion, resultant spots were enumerated using
a dissecting microscope. Precursor frequencies were calcu-
lated by subtracting the mean number of spots obtained
from the no-antigen control wells from the mean number
obtained in the experimental wells. A positive response
was defined as a precursor frequency that was both signif-
icantly (p < 0.05) greater than the mean of control no-
antigen wells and detectable (i.e., >1:100,000). In addi-
tion to non-antigen wells, myoglobin (Chemicon) and
media alone wells were included as an irrelevant protein
and negative control. Phytohemagglutinin (Sigma) incu-
bated with patient T cells at a concentration of 5 ug/ml
was used as a positive control for the ability of T cells to
respond to antigen.
ELISA for detection of antigen specific antibodies
Humoral immunity to HER-2/neu, tt, and CMV was
assessed using a standardized and validated enzyme-
linked immunosorbant assays (ELISA) that have been pre-
viously described [19]. Briefly, 96-well microtiter plates
(Dynex Technologies, Inc, Chantilly, VA) were coated
with antigen in alternating columns. Serially diluted, puri-BMC Immunology 2007, 8:21 http://www.biomedcentral.com/1471-2172/8/21
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fied human IgG (Sigma) provided a standard curve. Plates
were incubated overnight at 4°C. All wells were then
blocked with 100 uL/well of a filtered buffer of 10% phos-
phate-buffered saline (PBS)/1% bovine serum albumin
(BSA; Sigma), 100 uL/well, and incubated at room tem-
perature on a rocker for 4 hours. Plates were washed four
times with 10% PBS/0.5% Tween (Amersham Bio-
sciences, Piscataway, NJ) before addition of patient sera.
After serum incubation, plates were washed four times
with PBS/Tween and goat antihuman IgG-horseradish
peroxidase (HRP) conjugate (Zymed Laboratories, South
San Francisco, CA) added at a dilution of 1:50,000 (50 uL/
well) and incubated for 45 minutes at room temperature
on rocker. After a final PBS/Tween wash, developing rea-
gent was added (75 uL/well) and color reaction assessed
at an optical density (OD) of 640 nm until the well con-
taining the standard at a concentration of 0.16 ug/mL
evaluated at 0.3 OD. Reaction was then stopped with 75
uL/well 1N HCL and read at OD of 450 nm. The OD of
each serum dilution was calculated as the OD of the anti-
gen-coated wells minus the OD of the PBS/BSA-coated
wells. Values for each delta OD were calculated from the
log-log equation of the line for the standard curve on each
plate, as plotted by SOFTmax version 2.3 for Macintosh
(Molecular Devices Corp, Sunnyvale, CA). Positive and
negative controls were run on every plate. A sample from
a patient with HER-2/neu overexpressing breast cancer
was used as a positive control. Media alone and a sample
from a healthy donor were used as negative controls. A
sample was defined as positive if the value was greater
than the mean and two standard deviations of the previ-
ously analyzed reference population, 1.13 ug/ml for the
HER-2/neu assay, 9.98 ug/ml for the tt assay and 200 ug/
ml for the CMV assay.
Statistical analysis
Differences in magnitude of T cell responses to different
antigens were measured by one-way ANOVA. The rela-
tionship between antibody and T cell response was ana-
lyzed by linear regression. Analytic performance of the
proliferation assay and ELISPOT assay was evaluated by
plotting receiver operating characteristic (ROC) curves of
results and estimating area under the curve (AUC). All
analyses were performed using SPSS 13.0 for PC (SPSS,
Chicago, IL).
Abbreviations
AUC- Area under the curve.
CMV- Cytomegalovirus.
CV- Coefficient of variation.
ICD- Intracellular domain.
mLDA- Modified limiting dilution assay.
ELISPOT- Enzyme-linked immunosorbent spot.
ROC- Receiver operating characteristic.
SI- Stimulation index.
tt- Tetanus toxoid.
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